The National Institute of General Medical Sciences (NIGMS) awarded Dotquant LLC a $305,892 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to develop an innovative in vitro transcription kit for high-yield synthesis of chemically modified RNA. The project aims to combine the high efficiency of wild-type T7 RNA polymerase with the ability to incorporate modified nucleotides, enabling the affordable production of serum-stable RNA for biomedical research and therapeutic applications. By addressing key technical barriers, this new kit is expected to increase RNA synthesis yields by at least 10-fold over current best-performing solutions, significantly improving the affordability of RNA-based drugs and research tools.
Generated 3/4/25, 4:12 AM